Banco Santander S.A. cut its stake in Sanofi SA (NYSE:SNY) by 7.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 25,240 shares of the company’s stock after selling 1,910 shares during the quarter. Banco Santander S.A.’s holdings in Sanofi were worth $1,105,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Bessemer Group Inc. increased its holdings in Sanofi by 11.8% in the fourth quarter. Bessemer Group Inc. now owns 2,409 shares of the company’s stock valued at $104,000 after buying an additional 255 shares in the last quarter. OLD National Bancorp IN increased its position in shares of Sanofi by 2.4% during the 1st quarter. OLD National Bancorp IN now owns 11,434 shares of the company’s stock worth $506,000 after purchasing an additional 271 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Sanofi by 11.5% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,772 shares of the company’s stock worth $123,000 after acquiring an additional 286 shares during the last quarter. Global Retirement Partners LLC increased its holdings in shares of Sanofi by 28.0% during the 1st quarter. Global Retirement Partners LLC now owns 1,331 shares of the company’s stock worth $59,000 after acquiring an additional 291 shares during the last quarter. Finally, Stephens Inc. AR increased its holdings in shares of Sanofi by 1.3% during the 1st quarter. Stephens Inc. AR now owns 25,480 shares of the company’s stock worth $1,128,000 after acquiring an additional 336 shares during the last quarter. Institutional investors own 7.04% of the company’s stock.
Separately, TheStreet upgraded Sanofi from a “c+” rating to a “b-” rating in a research report on Friday, June 21st. Eight equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Sanofi has an average rating of “Hold” and an average target price of $51.00.
Sanofi (NYSE:SNY) last issued its earnings results on Friday, April 26th. The company reported $0.81 EPS for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.07. The business had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.34 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the company posted $1.28 earnings per share. On average, equities research analysts forecast that Sanofi SA will post 3.1 earnings per share for the current fiscal year.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: The risks of owning bonds
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.